Join
Live feed
·
PRReleasevia Quantisnow
Incyte Corp. logo

Incyte Announces 24-Week Long-Term Data from Phase 3 TRuE-AD4 Trial of Opzelura® (ruxolitinib) Cream in Adults with Moderate Atopic Dermatitis

ByQuantisnow·Wall Street's wire, on your screen.
INCY· Incyte Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track INCY (Incyte Corp.) and more on Quantisnow.